Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 32731 cream in mild to moderate atopic dermatitis
NCT02496546Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing LEO 32731 cream with LEO 32731 cream vehicle (2 arms). Primary endpoint: Total Sign Score at 3 weeks. Started Jul 2015; status: completed.
02
Drugs
orismilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02496546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496546.